Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Keros Therapeutics, Inc. (KROS)

Keros Therapeutics to receive $20 million Takeda milestone payment for elritercept

Positive Impact 3 of 5 product/contract Written later

Keros Therapeutics said it expects to receive a $20 million development milestone payment from partner Takeda after the first patient was dosed in the Phase 3 ELRiSE MF trial of elritercept. Keros expects to distribute 25% of the net cash proceeds from the payment to its stockholders after receipt.

Key points

  • $20 million development milestone payment under the elritercept license agreement with Takeda
  • Triggered by dosing of the first patient in the Phase 3 ELRiSE MF trial in myelofibrosis and anemia
  • Keros expects to distribute 25% of net cash proceeds from the payment to stockholders after receipt
  • Keros received a $200 million upfront payment in February 2025 and is eligible for milestones potentially exceeding $1.1 billion

The filing

CompanyKeros Therapeutics, Inc. (KROS)
Form8-K, current report
Filed with the SECSep 29, 2026, 8:01 AM ET
Accession number0001664710-26-000059

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.